SEC Comment Letter 0000000000-24-012983 to Evaxion A/S (EVAX)

Evaxion A/S
Date: Nov. 22, 2024 · CIK: 0001828253 · Accession: 0000000000-24-012983

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-283304

Date

November 22, 2024

Author

Not clearly detected

Form

UPLOAD

Company

Evaxion A/S

Letter

November 22, 2024 Christian Kanstrup Chief Executive Officer Evaxion Biotech A/S Dr. Neergaards Vej 5F 2970 Hørsholm Denmark Re:Evaxion Biotech A/S Registration Statement on Form F-1 Filed November 18, 2024 File No. 333-283304 Dear Christian Kanstrup : This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Michael D. Baird, Esq.

Show Raw Text

November 22, 2024
Christian Kanstrup
Chief Executive Officer
Evaxion Biotech A/S
Dr. Neergaards Vej 5F
2970 Hørsholm
Denmark
Re:Evaxion Biotech A/S
Registration Statement on Form F-1
Filed November 18, 2024
File No. 333-283304
Dear Christian Kanstrup :
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Michael D. Baird, Esq.

SecProbe.io